SHPG up +0.68% percent Today $SHPG High is at 204.10 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
SHPG up +0.68% percent Today $SHPG High is at 204.10 and the Low 202.15 with current volume of 207,296.

Recent News posted below.

Shire Plc American Depositary Shares SHPG other info.
http://investorshangout.com/Shire-Plc-SHPG-55423/

SHPG Shire Plc American Depositary Shares Recent Headline News

Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST

SHPG: 204.43 (+1.81), SNY: 47.31 (+0.63), FOLD: 6.64 (+0.95)

Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 204.43 (+1.81), SNY: 47.31 (+0.63), FOLD: 6.64 (+0.95)

Sucampo (SCMP) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 8:25AM CST
Sucampo Pharmaceuticals (SCMP) was a big mover last session, with shares rising over 7% on the day.
LCI: 47.69 (+0.81), SHPG: 204.43 (+1.81), SCMP: 11.86 (+0.56), CEMP: 13.87 (+0.27)

Research and Markets: North America Tissue Engineered Skin Substitutes Market Outlook to 2020: Key Players Organogenesis, Inc, Kinetic Concepts, Inc., Shire Plc & Smith & Nephew Plc.
Business Wire - Thu Nov 13, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bx55x/north_america) has announced the addition of the "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering.
SNN: 33.51 (+0.24), SHPG: 204.43 (+1.81)

North America Tissue Engineered Skin Substitutes Market Outlook to 2020: Key Players Organogenesis, Inc, Kinetic Concepts, Inc., Shire Plc & Smith & Nephew Plc.
M2 - Thu Nov 13, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vj74f/north_america) has announced the addition of the "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the North America Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Scope - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Tissue Engineered - Skin Substitutes market. - Global corporate-level profiles of key companies operating within the North America Tissue Engineered - Skin Substitutes. Companies Mentioned - Organogenesis, Inc. - Shire Plc - Kinetic Concepts, Inc. - Integra LifeSciences Holdings Corporation - Smith & Nephew Plc - Covidien plc - Molnlycke Health Care AB - BSN medical GmbH For more information visit http://www.researchandmarkets.com/research/8v...th_america
SNN: 33.51 (+0.24), IART: 47.71 (+0.07), SHPG: 204.43 (+1.81)

Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST

SHPG: 204.43 (+1.81), PFE: 29.96 (-0.38), AZN: 72.20 (-0.65), ABBV: 65.03 (+1.03), WAG: 66.55 (-0.38)

Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Pipeline Review, H2 2014 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Tue Nov 11, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/nwr23p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Lentigen Corporation - Shire Plc - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - idursulfase - idursulfase - FT-1050 - JR-032 - AGT-182 - LG-1041 - Recombinant Enzyme to Replace Iduronate-2-Sulfatase for Hunter Syndrome For more information visit http://www.researchandmarkets.com/research/nw...saccharido
FATE: 3.53 (-0.43), SHPG: 204.43 (+1.81)

Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 306.08 (+0.65), GILD: 101.14 (-0.92), SHPG: 204.43 (+1.81), ABBV: 65.03 (+1.03), CELG: 104.98 (+0.93)

The Zacks Analyst Blog Highlights: UBS, Shire and Mallinckrodt
PR Newswire - Mon Nov 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the UBS AG (NYSE:UBS-Free Report), Shire plc (Nasdaq:SHPG-Free Report) and Mallinckrodt plc (NYSE:MNK-Free Report).
SHPG: 204.43 (+1.81)

ECB in Action for Stimulus: 3 European Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:14AM CST
ECB is prepared for unconventional policy tools "if needed" to beat ultralow inflation.
MNK: 89.08 (+0.97), SHPG: 204.43 (+1.81), UBS: 17.41 (-0.13)

The Zacks Analyst Blog Highlights: AbbVie, Shire, Medtronic, Unilife and Derma Sciences
PR Newswire - Fri Nov 07, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Medtronic Inc. (NYSE:MDT-Free Report), Unilife Corporation (Nasdaq:UNIS-Free Report) and Derma Sciences Inc. (Nasdaq SCI-Free Report).
DSCI: 8.49 (+0.06), UNIS: 2.79 (-0.10), MDT: 69.32 (+0.37), SHPG: 204.43 (+1.81)

Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 64.70 (+1.76), JNJ: 108.26 (+0.10), PCYC: 135.03 (+0.60), SHPG: 204.43 (+1.81), MRK: 59.72 (+0.65), AMGN: 159.27 (+1.59)

Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 204.43 (+1.81), PFE: 29.96 (-0.38), MRK: 59.72 (+0.65), AZN: 72.20 (-0.65), TEVA: 57.88 (+0.81), ITCI: 14.69 (-0.46), ABBV: 65.03 (+1.03), BMY: 58.12 (+0.17), OMER: 19.54 (+0.56)

Top 2 MedTech Stocks, Poised to Gain on Earnings this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:36AM CST
Medical device is one of such sectors which are projected to be highly affected by the midterm election results.
DSCI: 8.49 (+0.06), MDT: 69.32 (+0.37), UNIS: 2.79 (-0.10), COV: 94.44 (+0.46), SHPG: 204.43 (+1.81), ABBV: 65.03 (+1.03), WAG: 66.55 (-0.38)

How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 211.00 (+12.35), VRX: 135.69 (+1.48), ACT: 249.59 (+5.82), SHPG: 204.43 (+1.81), ABBV: 65.03 (+1.03)

Shire to Participate at the Credit Suisse 2014 Global Healthcare Conference
PR Newswire - Thu Nov 06, 6:00AM CST
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it will be participating in the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at the Arizona Biltmore Hotel in Phoenix, Arizona. Flemming Ornskov, MD, Chief Executive Officer will present at 3:30 PM Mountain Standard Time (5:30 PM EST; 10:30 PM UK time).
SHPG: 204.43 (+1.81)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.51 (+0.61), ENDP: 67.10 (+0.84), AUXL: 32.30 (+0.13), SHPG: 204.43 (+1.81), DNDN: 0.13 (+0.02), SNSS: 1.84 (+0.17), ABBV: 65.03 (+1.03), SNY: 47.31 (+0.63), MNKD: 6.15 (-0.01), XOMA: 3.98 (+0.06)

Critical Alerts For Apple, LightInTheBox, Time, 21st Century Fox and Shire Released By InvestorsObserver
PR Newswire - Wed Nov 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, LITB, TIME, FOXA and SHPG.
TIME: 22.40 (-0.03), SHPG: 204.43 (+1.81), FOXA: 35.23 (+0.12), AAPL: 114.09 (-0.09), LITB: 8.02 (-0.26)

Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 59.72 (+0.65), SHPG: 204.43 (+1.81)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 220

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 263

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 82

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 118

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 26

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 8

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 194

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 26

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 86

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 68

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading

Top 5 Most Recently Viewed Articles

Michael Baker International Enhances Pavement Management Strategies

Updated Category News Views 313

Michael Baker International Teams Up with CVAG Michael Baker International, a well-known leader in engineering and consulting services, has recently been selected by the Coachella Valley Association of Governments (CVAG) for an important project focused on improving the area's pavement condition assessments. This partnership marks a significant step toward enhancing the...

Continue Reading
Fidus Investment Corporation Announces $100 Million Note Offering

Updated Category News Views 307

Fidus Investment Corporation's Recent Offering Announcement Fidus Investment Corporation (NASDAQ: FDUS) has recently made a significant announcement regarding its financial strategy. The company has priced an underwritten public offering of 6.750% notes, with an aggregate principal amount of $100 million, due in 2030. This initiative is aimed at strengthening its capital...

Continue Reading
WillScot Strengthens Board with New Appointment to Drive Growth

Updated Category News Views 49

WillScot Appoints Worthing Jackman to Board of Directors WillScot Holdings Corporation (NASDAQ: WSC), a leader in flexible space and storage solutions, has made a strategic move by appointing Worthing Jackman to its Board of Directors. This significant addition is aimed at reinforcing the company's growth strategy and bolstering its financial and operational performance....

Continue Reading
National Press Club Reacts to Pentagon's New Media Restrictions

Updated Category News Views 510

Concerns Regarding Pentagon's Media Access Restrictions Recently, the National Press Club leadership voiced significant concerns about new media restrictions imposed by the Pentagon. A statement from the club highlighted that these restrictions threaten transparency and reduce public access to information critical for accountability. Impact on Journalistic Integrity...

Continue Reading
Dogecoin and Shiba Inu Surge: A New Era for Meme Coins

Updated Category News Views 100

A Look at the Recent Surge in Dogecoin and Shiba Inu Recently, Dogecoin and Shiba Inu, both leaders in the meme coin market, have experienced notable price spikes. Dogecoin's value has risen by 4.5%, while Shiba Inu has jumped an impressive 8%. These increases follow important economic news about a cut in interest rates, which is bringing renewed optimism among crypto...

Continue Reading